Abstract:521 Background: In 1946, nearly 90% of patients diagnosed with metastatic Testicular Germ Cell Tumor (TGCT) succumbed to the disease within a year. In the present day, over 90% of such patients are successfully cured. However, there is a remaining 10% of patients have tumors that consist of chemotherapy-resistant forms of TGCT, such as yolk sac tumors and teratomas. This underlines the need for developing biomarkers that can guide the choice between additional chemotherapy and surgical intervention. MicroRNAs (miRNAs), non-coding RNA molecules that control post-transcriptional modifications, have shown promise in identifying TGCTs. Research has particularly highlighted the overexpression of miR-371a-3p and miR-375-3p in TGCTs. Nevertheless, these miRNAs are not effective in distinguishing between teratomas and other TGCT types. The Cancer Genome Atlas (TCGA), a publicly accessible database, offers clinical and miRNA data on various tumors, including TGCTs. Our objective is to leverage TCGA to identify miRNAs that can be used to classify TGCTs containing teratomas from those that do not. Methods: Between 2001 and 2013, TCGA gathered a total of 135 primary TGCT samples. We group these tumors into those without teratomas and those with any teratomatous components. We used EdgeR, a Bioconductor package designed for differential expression analysis of RNA that accounts for both biological and technical variation. A false discovery rate of less than 1e-8 was applied. A heatmap was generated to display the hierarchical clustering of differentially expressed miRNAs. Results: Based on the above cut-off, a panel of 50 miRNAs of differentially expressed miRNA were used to generate a hierarchical clustering that showed clear clustering between the two groups. Notably, tumor suppressor miRNAs such as hsa-mir-203a, hsa-mir-199, and hsa-mir-152, which are usually downregulated in non-teratoma TCGT, are overexpressed in teratomas. Other miRNA including hsa-mir-146a and hsa-mir-3607, which are downregulated tumor suppressors for non-TCGT are also downregulated in teratomas but not in teratoma-free TGCT. Conclusions: Despite the high cure rate for TGCTs, tumors containing chemotherapy-resistant teratomas still contribute to elevated mortality rates. Utilizing TCGA data, we identified a set of miRNAs that are effective in distinguishing between teratoma-containing and teratoma-free TGCTs. This miRNA panel has the potential to inform decisions related to surgical treatment plans and provide further insight into the biology of the disease.

Testicular Germ Cell Tumor Tissue Biomarker Analysis: A Comparison of Human Protein Atlas and Individual Testicular Germ Cell Tumor Component Immunohistochemistry

[Expression of Human Testis Development Related Gene 1 in Testicular Cancer Detected by Tissue Microarray].

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Scanning of novel cancer/testis proteins by human testis proteomic analysis.

Identification of New Biomarkers in Immune Microenvironment of Testicular Germ Cell Tumour

Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma

Genome-wide analysis of cancer/testis gene expression

Identification of novel potential genes in testicular germ cell tumors: A transcriptome analysis

Detecting predicted cancer-testis antigens in proteomics datasets of healthy and tumoral samples

Testicular Germ Cell Tumors: a Clinicopathological and Immunohistochemical Analysis of 145 Cases

Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors

RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors

Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins

Role of Hub Genes in the Occurrence and Development of Testicular Cancer Based on Bioinformatics

Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.

The Utility of Immuno-Nutritional Scores in Patients with Testicular Germ Cell Tumors

Comprehensive characterization of cancer‐testis genes in testicular germ cell tumor

Comparative observational study of serum neoplastic biomarker and immunohistochemistry in 28 cases of intracranial germ cell tumors

MicroRNA-371a-3p-The Novel Serum Biomarker in Testicular Germ Cell Tumors

Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors

TdT expression in germ cell tumours: a possible immunohistochemical cross-reaction and diagnostic pitfall